Comparative Pharmacology
Head-to-head clinical analysis: MELPHALAN versus VIVIMUSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELPHALAN versus VIVIMUSTA.
MELPHALAN vs VIVIMUSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melphalan is an alkylating agent that forms interstrand crosslinks with DNA, inhibiting DNA replication and transcription, leading to cell death.
VIVIMUSTA is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
Melphalan 0.25 mg/kg/day orally for 4 consecutive days, repeated every 4-6 weeks; or 16 mg/m² intravenously over 15-20 minutes at 2-week intervals for 4 doses.
100 mg/m2 intravenously over 30 minutes on days 1-3 of a 21-day cycle.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (IV); prolonged in renal impairment (up to 3-4 hours).
Clinical Note
moderateMelphalan + Digoxin
"Melphalan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMelphalan + Digitoxin
"Melphalan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMelphalan + Deslanoside
"Melphalan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMelphalan + Acetyldigitoxin
"Melphalan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min).
Renal: 10-15% unchanged; hepatic metabolism (20-30%) with biliary excretion of metabolites; fecal: <5%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category D/X
Category C
Alkylating Agent
Alkylating Agent